Human glucagon

European Pharmacopoeia (EP) Reference Standard

Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
MDL number:
PubChem Substance ID:
Pricing and availability is not currently available.


pharmaceutical primary standard




certificate is enclosed in each package

mfr. no.


Featured Industry

Pharmaceutical (small molecule)



storage temp.




InChI key


Gene Information

human ... GCGR(2642)

Looking for similar products? Visit Product Comparison Guide

Amino Acid Sequence


General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Glucagon is a 29-amino acid peptide hormone secreted by pancreatic α-cells that raises blood glucose and (indirectly) insulin levels. Glucagon acts via a G protein-coupled receptor, which results in the release of glucose 1-phosphate from glycogen.


Unit quantity: 2.94 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference subtance catalogue.

Other Notes

Highly-conserved 29-amino acid polypeptide hormone produced by the pancreatic cells.
Sales restrictions may apply.



NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
The BMJ and Dispatches gave only one side of the story.
Richard I G Holt
BMJ (Clinical research ed.), 347, f4379-f4379 (2013-07-12)
Investigations editor's reply to Holt and to Barnett and O'Hare.
Deborah Cohen
BMJ (Clinical research ed.), 347, f4383-f4383 (2013-07-12)
Incretin therapy: should adverse consequences have been anticipated?
Edwin Gale
BMJ (Clinical research ed.), 346, f3617-f3617 (2013-06-12)
Patricia I Mighiu et al.
Nature medicine, 19(6), 766-772 (2013-05-21)
Glucagon activates hepatic protein kinase A (PKA) to increase glucose production, but the gluco-stimulatory effect is transient even in the presence of continuous intravenous glucagon infusion. Continuous intravenous infusion of insulin, however, inhibits glucose production through its sustained actions in...
A L McCall et al.
Minerva endocrinologica, 38(2), 145-163 (2013-06-05)
Type 1 diabetes is a disorder where slow destruction of pancreatic β-cells occurs through autoimmune mechanisms. The result is a progressive and ultimately complete lack of endogenous insulin. Due to β-cell lack, secondary abnormalities in glucagon and likely in incretins...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.